Uses and misuses of definitions of genetic polymorphism. A perspective from population pharmacogenetics.
作者信息
Arias T D, Jorge L F, Barrantes R
出版信息
Br J Clin Pharmacol. 1991 Jan;31(1):117-9. doi: 10.1111/j.1365-2125.1991.tb03870.x.
Abstract
摘要
相似文献
1
Uses and misuses of definitions of genetic polymorphism. A perspective from population pharmacogenetics.基因多态性定义的应用与误用。群体药物遗传学视角。
Br J Clin Pharmacol. 1991 Jan;31(1):117-9. doi: 10.1111/j.1365-2125.1991.tb03870.x.
2
Pharmacogenetics.药物遗传学
Prim Care. 2004 Sep;31(3):543-59, ix. doi: 10.1016/j.pop.2004.04.009.
3
Pharmacogenetics: the Rx perspective.药物遗传学：处方视角。
Expert Rev Mol Diagn. 2001 Sep;1(3):255-63. doi: 10.1586/14737159.1.3.255.
4
Cardiovascular pharmacogenomics.心血管药物基因组学
Circulation. 2003 Dec 23;108(25):3071-4. doi: 10.1161/01.CIR.0000110626.24310.18.
5
6
A pharmacogenomics primer.药物基因组学入门
J Clin Pharmacol. 2007 Sep;47(9):1087-103. doi: 10.1177/0091270007303768. Epub 2007 Jul 30.
7
[Prospects of medicinal use of achievements in genomics: the beginning of era of complete genome medical genetics].[基因组学成果的药用前景：全基因组医学遗传学时代的开端]
Patol Fiziol Eksp Ter. 2001 Jan-Mar(1):3-22.
8
Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications.性功能障碍的药物遗传学和药物基因组学：现状、差距和潜在应用。
Pharmacogenomics. 2009 Oct;10(10):1625-44. doi: 10.2217/pgs.09.104.
9
Race, ethnicity, ancestry, and pharmacogenetics.种族、族裔、血统与药物遗传学。
Mt Sinai J Med. 2010 Mar-Apr;77(2):133-9. doi: 10.1002/msj.20168.
10
Pharmacogenetics of osteoporosis-related bone fractures: moving towards the harmonization and validation of polymorphism diagnostic tools.骨质疏松症相关骨折的药物遗传学：朝着多态性诊断工具的协调和验证方向发展。
Pharmacogenomics. 2010 Sep;11(9):1287-303. doi: 10.2217/pgs.10.116.
引用本文的文献
1
Inferring intelligence of ancient people based on modern genomic studies.根据现代基因组研究推断古人的智力。
J Hum Genet. 2022 Sep;67(9):527-532. doi: 10.1038/s10038-022-01039-8. Epub 2022 May 9.
2
Transcription Factor AP4 Mediates Cell Fate Decisions: To Divide, Age, or Die.转录因子AP4介导细胞命运决定：分裂、衰老或死亡。
Cancers (Basel). 2021 Feb 8;13(4):676. doi: 10.3390/cancers13040676.
3
Pharmacogenetics in Ghana: reviewing the evidence.加纳的药物遗传学：证据综述。
Ghana Med J. 2011 Jun;45(2):73-80. doi: 10.4314/gmj.v45i2.68932.
本文引用的文献
1
Pharmacoanthropology: outline, problems, and the nature of case histories.药物人类学：概述、问题及病例史的本质
Fed Proc. 1984 May 15;43(8):2314-8.
2
Human pharmacogenetics: Introduction.人类药物遗传学：引言
Fed Proc. 1984 May 15;43(8):2295-7.
3
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.日本人群与白种人群之间在异喹胍和甲妥英羟基化遗传多态性上的种族差异。
Clin Pharmacol Ther. 1985 Oct;38(4):402-8. doi: 10.1038/clpt.1985.194.
4
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.一项关于决定异喹胍多态性羟化的遗传和环境因素的家族研究。
Clin Pharmacol Ther. 1985 Oct;38(4):394-401. doi: 10.1038/clpt.1985.193.
5
Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans.加纳人和德国人之间司巴丁氧化的种族间差异。
Eur J Clin Pharmacol. 1985;28(1):79-83. doi: 10.1007/BF00635712.
6
Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians.加纳人群中异喹胍/苯乙双胍与司巴丁氧化共调节控制的解离
Clin Pharmacol Ther. 1985 May;37(5):512-21. doi: 10.1038/clpt.1985.81.
7
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation.尼日利亚人美托洛尔和异喹胍的代谢：缺乏多态性氧化的证据。
Clin Pharmacol Ther. 1986 Oct;40(4):387-94. doi: 10.1038/clpt.1986.195.
8
The detection of polymorphic drug oxidation--some theoretical and practical aspects.多态性药物氧化的检测——一些理论和实践方面
Prog Clin Biol Res. 1986;214:413-24.
9
No evidence for the presence of poor metabolizers of sparteine in an Amerindian group: the Cunas of Panama.在一个美洲印第安人群体——巴拿马的库纳族人中，没有证据表明存在司巴丁代谢不良者。
Br J Clin Pharmacol. 1986 May;21(5):547-8. doi: 10.1111/j.1365-2125.1986.tb02841.x.
10
The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers.巴拿马库纳美洲印第安人中司巴丁的氧化代谢：缺乏代谢缺陷者的证据
Clin Pharmacol Ther. 1988 Apr;43(4):456-65. doi: 10.1038/clpt.1988.58.
Zotero 插件